General Information of Drug (ID: DMRLZA1)

Drug Name
ZW25
Synonyms Zanidatamab
Indication
Disease Entry ICD 11 Status REF
Biliary tract cancer 2C17 Phase 2 [1]
Breast cancer 2C60-2C65 Phase 2 [2]
Oesophagogastric junction cancer 2B71.Z Phase 2 [2]
Ovarian cancer 2C73 Phase 1 [3]
Drug Type
Antibody
Cross-matching ID
TTD ID
D0AJ9V
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 ClinicalTrials.gov (NCT04466891) A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04224272) A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)